Milnacipran versus other antidepressive agents for depression

Milnacipran: recent findings in depression

Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) which was first approved for the treatment of major depressive episodes in France in December 1996. It is currently marketed for this indication (as Ixel ® , Toledomin ® , Tivanyl ® or Dalcipran ®) in over 45 countries worldwide including Japan. It was approved for the management of fibromyalgia in the US in 2009. This supp...

Antifungal agents: Polyene, azole, antimetabolite, other and future agents

Antifungals have always been considered as one of the astonishing discoveries of the 20th century. This is correct, but the real marvel is the development of antifungal resistance in hospitals, communities, and the environment concomitant with their use. Fungal infections have emerged as an important clinical threat, with significant associated morbidity and mortality.  This study is desig...

Efficacy and Safety of Milnacipran Versus Venlafaxinein Major Depression in Indian Patients

The objective of the study was to compare the efficacy and safety ofmilnacipran and Venlafaxine in major depressive disorder. The study was conducted in 120 patients suffering from major depressive disorder as per DSM-IV criteria. Patients were randomized to two groups and were given milnacipran (25, 50mg BD) and venlafaxine(75, 150mg OD) for 8 weeks. The primary efficacy parameter was the Hami...

[Antidepressive agents to children and adolescents: continuous restriction is justified].

[Cardiotoxicity of tricyclic antidepressive agents. (Phenothiazines and imipramines)].